Passage Bio Welcomes Tom Kassberg to Board of Directors
Passage Bio, Inc. (PASG)
Company Research
Source: GlobeNewswire
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases. "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission forward during this critical time for the organization," said Will Chou, M.D., president and chief executive officer of Passage Bio. "Mr. Kassberg brings a wealth of experience from his time at Ultragenyx, where he leads business development and alliance management and has directly contributed to
Show less
Read more
Impact Snapshot
Event Time:
PASG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PASG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PASG alerts
High impacting Passage Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PASG
News
- The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development [Yahoo! Finance]Yahoo! Finance
- Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.MarketBeat
- Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $13.00 price target on the stock.MarketBeat
- Passage Bio Achieves Milestones in Gene Therapy Trials [Yahoo! Finance]Yahoo! Finance
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business HighlightsGlobeNewswire
PASG
Earnings
- 11/13/24 - Miss
PASG
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/14/24 - Form SCHEDULE
- 11/14/24 - Form SC
- PASG's page on the SEC website